Phase II Study Evaluating the Efficacy of Tacrolimus Extended Release Tablets to Twice Daily Tacrolimus Dosing Regimen (Veloxis)
Phase II, Single-Center, Open-Label Study Evaluating the Comparable Efficacy of Tacrolimus Extended Release Tablets (Envarsus®) to the Standard of Care (SOC) Twice Daily Tacrolimus (Prograf®) Dosing Regimen
Sponsor: Baylor Research Institute
This PHASE2 trial investigates Compliance, Patient and Graft Failure and is currently completed. Baylor Research Institute leads this study, which shows 10 recorded versions since 2017 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
10 versions recorded-
Nov 2025 — Present [monthly]
Completed PHASE2
Status: Unknown → Completed
-
Feb 2025 — Nov 2025 [monthly]
Unknown PHASE2
Status: Active Not Recruiting → Unknown
-
Sep 2024 — Feb 2025 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Feb 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 5 earlier versions
-
Jan 2021 — Feb 2023 [monthly]
Active Not Recruiting PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Aug 2019 — Aug 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Aug 2019 [monthly]
Recruiting PHASE2
-
Dec 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Baylor Research Institute
For direct contact, visit the study record on ClinicalTrials.gov .